Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | DDX3X | O00571 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700801 | 0.88 | ITGB1 (0.67) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL5852186 | 0.86 | DDX3X (0.70) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL812756 | 0.86 | DDX3X (0.80) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL1275926 | 0.84 | RAB9A (0.75) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL687547 | 0.83 | RAB9A (0.66) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL17084259 | 0.83 | RAB9A (0.67) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL3460449 | 0.83 | DDX3X (0.70) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL6799221 | 0.82 | RAB9A (0.73) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL17079620 | 0.81 | RAB9A (0.68) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL17079626 | 0.81 | RAB9A (0.73) | RAB9ANPC1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| EP-3116852-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | University of Warwick (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | DDX3X, DDX1, DDX5 | RAB9A 873/4885NPC1 2429/4885MAPT 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.